IJMPR, 2026, 10(3), 19-28 ISSN: 2319-5878

INTERNATIONAL JOURNAL OF MODERN PHARMACEUTICAL RESEARCH

www.ijmpronline.com

Review Article

Impact Factor: 7.533

Coden USA: IJMPR3

PHARMACEUTICAL POLYMERS IN SOLID DOSAGE FORM DESIGN: A COMPREHENSIVE REVIEW OF NATURAL, SEMI-SYNTHETIC, AND SYNTHETIC POLYMERS

[*1,2]Oday Sajjad Alsawad

[1]Department of Pharmaceutics, College of Pharmacy, University of Basrah, Basrah, Iraq.
[2]Department of Pharmacy, Al-Manara College for Medical Sciences, Maysan, Iraq.

Article Received on: 01/02/2026 **Article Revised on: 21/02/2026** **Article Published on: 01/03/2026**

***Corresponding Author**

Oday Sajjad Alsawad

Department of Pharmaceutics, College of Pharmacy, University of Basrah, Basrah, Iraq.

https://doi.org/10.5281/zenodo.18812523

How to cite this Article: [*1,2]Oday Sajjad Alsawad (2026). Pharmaceutical Polymers In Solid Dosage Form Design: A Comprehensive Review Of Natural, Semi-Synthetic, And Synthetic Polymers. International Journal of Modern Pharmaceutical Research, 10(3), 19–28.

ABSTRACT

Pharmaceutical polymers are key ingredients in the design and performance of solid dosage forms, which directly affect drug release behavior, stability, manufacturability and bioavailability. Their functional roles vary from being included as a binder and disintegrant in their immediate-release counterparts to acting as matrix formers, coating agents and release modifiers in the controlled and modified-release systems. The aim of this narrative review is to critically assess pharmaceutical polymers for solid dosage form design considering mainly their classification, functional mechanism, industrial use, and regulatory issue. A structured search of the literature was done using the major scientific databases looking for publications from the last 10-15 years. Evidence from formulation science and industrial experience underscores that while innovation in polymer use for sophisticated release control strategies or enhanced product performance is made possible by polymer formulation, polymer choice and processing introduces great challenges with regard to variability, scale-up, quality control, and regulatory compliance. An integrated understanding of polymer chemistry, formulation function and manufacturing constraints are therefore very essential to successful solid dosage form development.

KEYWORDS: *Pharmaceutical Polymers, Natural Polymers, Semi Synthetic Polymers, Synthetic Polymers, Matrix Systems, Industrial Pharmacy.*

INTRODUCTION

Solid oral dosage forms (e.g. tablets, capsules, and multiparticulates) are still the dominant forms of pharmaceutical products worldwide due to a combination of dose accuracy, chemical and microbiological stability, patient convenience and relatively efficient manufacturing on a large scale. Within these dosage forms, polymers are enabling materials that are responsible for not only product manufacturability (flow, compressibility, granulation behavior and coating performance) but also determine critical clinical attributes such as disintegration time, dissolution rate and their robustness to gastrointestinal variability. The truth is that polymer-based film coating and matrix systems are key industrial instruments for enhancing the aesthetic and swallowability of coatings, as well as protecting the moisture- or light-sensitive API, or ensuring delayed or prolonged release when a drug is not desired to be immediately released upon administration.[1]

Over the past decade, with the progress in polymer chemistry and material characterization, the "polymer toolbox" available in industrial pharmacy has been increased and the selection of polymers has been moved from a rather empirical choice for the excipients to a more mechanistic, structure--function approach. Semi-synthetic cellulose derivatives (especially hydroxypropyl methylcellulose, HPMC/hypromellose) are an example of this evolution: variation of the pattern of substitution, viscosity grade and molecular weight distribution can be exploited to control binding, film formation, gel layer formation in hydrophilic matrices and, finally, the release kinetics in solid dosage forms. Importantly, these same variables can simultaneously affect processing windows (e.g. compaction sensitivity, coating rheology, and drying behavior), as such polymer choice can be a fundamental determinant of both the performance of a therapeutic and of a viable industrial process.[2]

Synthetic polymers also allow for greater design flexibility in the solid dosage form with pH-regulated

solubility, release and permeability. The enteric coating, sustained release membranes, and site-specific delivery applications are prominent applications of the methacrylate copolymers (e.g., Eudragit(R) families) due to their ionic functional groups that permit the dissolution and diffusion of the compound to be controllable in the physiologic pH ranges. While these polymers can provide complex release profiles, their successful implementation at an industrial level dictates close attention to aspects of polymer grade, compatibility with plasticizers, uniformity and coating uniformity and post-coating curing - factors that have a direct impact on batch reproducibility and in vivo release behavior.[3] A major understood limiting constraint is that polymer "performance" is not only a material property, but rather is a function of variability of the supplier, variability of processing history, and polymer-API-excipient interactions. Emerging evidence in complex system from solid dispersions and polymer stabilized system have demonstrated that slight variations in excipient characteristics can cause a shift in crystallization risk and long term physical stability - issues that are translated to shelf life uncertainties and possible changes in bioavailability. For industrial pharmacy, this provides further support for the need to review polymers not only in terms of the intended function (binder, disintegrant, matrix former, coating agent) but also in terms of the risk of variation and control strategy over the lifecycle of the product.[4]

Acceptance by the regulators is just as decisive. Many established polymers have had long histories of safe use and unambiguous compendial specifications, however, it is difficult to introduce novel excipients (including new polymer chemistries, or new exposure scenarios) because regulators usually assess excipients mostly in the context of a finished drug product, which creates disincentives for polymer innovation. These barriers have been raised by EU-focused regulatory analyses: An evidentiary requirement and uncertainty about the qualification of novel excipients.[5] In parallel, there is growing policy and scientific debate for precompetitive approaches to excipient research that excipients - in particular polymers - should be viewed as "infrastructure" for pharmaceutical innovation rather than an exclusive formulation component.[6] Reflecting in some of these ways, the US food and drug administration (FDA) has been pursuing the search for mechanisms to enable earlier, standalone engagement about novel excipients through pilot initiatives that aim to reduce the regulatory uncertainty and spur innovation.[7] Accordingly, this review addresses the pharmaceutical polymers in solid dosage form design from an industrial pharmacist perspective, highlighting (i) the polymers classification into natural, semi-synthetic, and synthetic polymers; (ii) the role of polymers in immediate- and modified-release systems; and (iii) pharmaceutical manufacturing, quality/regulatory considerations of the polymers that dictate their practical adoption.

1. Role of Polymers in Industrial Pharmacy

In solid oral dosage forms, pharmaceutical polymers serve as more than "inactive" ingredients, serving as material design tools to determine (i) whether or not a process is manufacturable (at scale) and (ii) whether or not a final dosage form exhibits the intended therapeutic performance. Modern industrial pharmacy increasingly recognizes the multifunctional nature of polymers as excipients for controlling the flow of powders, the granulation of powders, compatibility, disintegration processing kinetics, release mechanisms, stability and patient acceptability - often simultaneously. This multifunctionality is one reason that solid dosage manufacturing is continuing to evolve towards greater understanding of excipients and better connections between materials and processes, particularly given that formulations are becoming more complex and APIs more difficult.[8]

At the point of manufacturing, polymers play a major role in the formation of granules and the robustness of the tablet. Polymeric binders enhance the cohesion and mechanical integrity of a material by influencing the formation of liquid bridges (in the case of wet granulation) or particle bonding (in the case of dry granulation/direct compression) and also affect the downstream compaction and friability of the resulting material. Importantly, molecular weight of polymers and binder concentration can affect viscosity and wetting conditions and will change the granule structure and ultimately the dissolution characteristics - thus the same "binder class" can behave differently depending on grade and loading. A good example is that one observes flow and dissolution sensitivity to binder type (i.e. povidone grades, copovidone, cellulose derivatives) and binder content in a granulated system and this solely strengthens the reason why binder choice is also a process decision.[9] For tablet disintegration, polymeric superdisintegrants (e.g., crospovidone, croscarmellose sodium, sodium starch glycolate) provide a good example of how maps the beaten polymer chemistry to product performance. Their functionality printed on functional-related characteristics (FRCs) such as degree of crosslinking/substitution, particle size distribution, viscosity-related behavior, and liquid uptake properties variation thereof can translate into meaningful differences in disintegration time, and consequently, in vivo onset of action for immediate release products. This makes disintegrants a prime example of why the goal of industrial pharmacy is the variability in the control of excipients, and meaningful material specifications beyond "compendial pass/fail".[10]

In the modified-release (MR) systems polymers are preferentially used as matrix formers, to control water ingress, gel formation, diffusion and erosion - to provide the release "architecture" of the dosage form. However, the hydration of polymers can also add to the manufacturing risks. In the case of continuous twin-screw wet granulation of hydrophilic matrix systems,

rapid polymer swelling has been shown to be associated with non-uniform distribution of API according to granule size fractions, which increases potential content uniformity issues downstream - an explicitly industrial (not purely formulation) challenge. Notably, polymer grade parameters (such as viscosity and substitution-related parameters) can be relevant parameters in such situations that contribute to such consequences in continuous processing applications.[11] Polymers are also equally important at the product interface in the form of coatings: film coatings can be used to protect moisture / oxygen-sensitive APIs, to mask taste, to increase swallowability and for functional behaviour (enteric protection or MR). Also, coating success is highly related to polymer film formation and mechanical properties, as glass transition temperature (Tg), the plasticization behavior and environmental sensitivity are then practical determinants of robustness in a manufacturing, storage and distribution environment.[12]

Due to the often high fraction of a formulation involved with polymers, excipient variability is a recurring risk factor for industries. Extra variability in raw materials, variation in suppliers/manufacturing processes, and noise in measurement systems can transition into making it hard to see the "signal" of the actual impact on product performance. Recent industrial facing analyses underpin how structure like methodologies and the use of structured data (e.g. multivariate analysis) can be used to identify sources of variability, strengthen control strategies with suppliers and defend a more consistent regulatory design space across the commercial life-cycle.[13] Taken together, polymer choice in industrial pharmacy should be viewed as a decision of material - process - performance and not a decision derived from a catalog: polymer molecular structure and grade characteristics (MW distribution, substitution patterns, Tg, etc.) determine processability and dosage form function, and even more of late in the manufacturing paradigms (including additive manufacturing routes) where thermal/mechanical process windows are narrow and polymer properties become directly rate limiting.[14]

Figure 1: Schematic representation of functional roles of pharmaceutical polymers in the design of solid dosage forms (binder, disintegrant, matrix former, coating agent, stabilizer)

2. Classification of Pharmaceutical Polymers

Pharmaceutical polymers present in solid dosage forms are generally divided according to their origin and extent of chemical modification as natural polymers, semi-synthetic polymers, and synthetic polymers. In reality, this classification is not just an academic one: The origin has a strong influence on variability risk, supply consistency, impurity/microbial profiles and finally on the robustness of industrial manufacturing. In the field of the development of modern formulations, particularly those for complex solids such as amorphous solid dispersions and functional coatings, the use of polymers becomes increasingly defined by information on the reliable potential ability of a polymer for achieving a specific target function (e.g. binding, disintegration control, matrix release, enteric protection) on a larger scale and within realistic process windows.[15] Natural polymers (e.g., starches, gums, alginates, chitosan, gelatin), while attractive because of the biocompatibility, wide functionality and high patient acceptance, are often subject to a higher degree of variability from lot-to-lot due to the fact that their properties are dependent on biological source, harvest/processing conditions and purification degree. This can have an impact on key performance attributes such as viscosity, swelling, gel strength and ionic sensitivity-all of which will directly influence tablet ability, disintegration and reproducibility of release.[16]

Semi-synthetic polymers are usually made from natural backbones (particularly cellulose) which are chemically altered to give them consistency and to tailor the performance. Common examples are HPMC, EC, CMC-Na and HPMCAS. Their value in industrial pharmacy is in the inherently more predictable balance that can be obtained with respect to processability (i.e. flow, compressibility, coating performance) and functional control (matrix formation, film formation, moisture modulation, pH-dependent solubility), without requiring the complexity of control of substitution patterns and molecular weight distributions.[17] Synthetic polymers (e.g., PVP, PEG, polymethacrylates, polyvinyl acetate derivatives) are generally linked with a more reliable manufacturing, the ability to tune physicochemical parameters and the wide spectrum of use (i.e., binders, solubilizers, precipitation inhibitors, film formers, pore formers, etc.). Their industrial application is aided by well-defined grades and specifications, although it is necessary to pay attention to residual monomers, hygroscopicity (partially) and long term stability behavior in moisture/thermal stress[18,19], excipient variability - including particle attributes of polymers, moisture content and rheological differences can measurably affect performance of oral solid dosage forms and reinforces the need for classification of polymers to couple with risk-based control strategies during development and scale-up.[20]

Table 1: Pharmaceutical polymers classification pharmaceutical polymers used in solid dosage forms with examples and main functions.

Polymer class	Typical examples	Key properties (very brief)	Primary functions in solid dosage forms
Natural	Starch, alginate, chitosan, gelatin, acacia	Bio-derived; higher variability	Binder, disintegrant, matrix former, mucoadhesion, viscosity modifier
Semi-synthetic	HPMC, EC, CMC-Na, HPMCAS	Modified biopolymer; more consistent	Binder, controlled-release matrix, film/coat former, enteric/pH-trigger (some), stabilizer
Synthetic	PVP, PEG, polymethacrylates, carbomers	Highly tunable; defined grades	Binder, solubilizer/ASD carrier, film coating/enteric (some), pore former, plasticizer

3. Polymers in Immediate-Release Solid Dosage Forms

Immediate-release (IR) solid dosage forms have been designed to rapidly dissolve and produce a dissolution profile that is conducive to good onset of action. In this regard polymers are mainly used in the form of binders (to provide for mechanical integrity of the product during compression, handling and packaging) and disintegrants/superdisintegrants (to allow rapid break-up of the compact into pieces that are efficiently dissolved). The most fundamental formulation problem is that the same polymer "architecture," which enhances compactibility and robustness, can also provide resistance to liquid penetration and slow disintegration rates, which means that IR performance is often a result of maintaining a balance between the binder driven aspect of strength and the disintegrant driven aspect of rupture and wettability. Evidence-based discussions of functional-related characteristics (FRCs) revealed that superdisintegrant performance is dependent upon several polymer attributes including degree of crosslinking/substitution, particle size, viscosity/gel-forming tendencies, liquid uptake behavior and impurity/reactivity profiles whose characteristics can be highly formulation- and process-dependent.[21]

Mechanistically, disintegration in IR tablets is generally promoted in combination of wicking/capillary uptake by the tablet material; swelling/strain generation; return of particle deformation, and the measurement of the actual mechanism can vary depending on the polymer type and microstructure. A practical implication for industry is that "equivalent" compendial grades can, however, behave differently in actual processes, especially where changes in, for example, lubrication, compression force, granule porosity, or water activity, will produce a change in the disintegration pathway. In continuous or semi-continuous manufacturing routes disintegrant location may be determinative: In a systematic evaluation of the disintegration characteristics of IR tablets manufactured via twin screw melt granulation, extra-granular disintegration agent addition led to faster disintegration and dissolution than intra-granular addition and performance varied between common superdisintegrants (i.e. crospovidone vs. croscarmellose sodium vs. sodium starch glycolate), underlining the modulating effect of processing history and spatial distribution on the functionality of polymer.[22]

Binders employed in IR systems (e.g. povidones, cellulose derivates) are thus chosen to enhance powder flow/granulation behavior and tablet tensile strength, but an increased level of binder and higher compression pressures may lead to a higher risk of slower disintegration as a result of decreased pore connectivity and limited liquid ingress. In an industrially relevant context of wet granulation, tablet ability improvements resulting from binder concentration and pressure compression were associated with trade-offs with the disintegration and it was dependent on the more general excipient system (such as filler choice) as well as disintegrant choice/localization.[23] Compensatory

evidence suggests that the type and average molecular weight of the binder(s) can alter release behavior in such a way that the higher molecular weight binders were linked with slower in vitro release in the granulated system, highlighting the potential to adjust the dissolution (especially early-time dissolution) course using polymer choice even with the aim of immediate release.[24] Finally, IR robustness demands consideration of batch-to-batch variation of polymeric excipients and other related materials that are used at scale. A Quality by Design study to assess several microcrystalline cellulose (MCC) grades / MCC manufacturers, showed that the variability in the excipients can alter the design space and have a measurable impact on critical quality attributes (e.g., dissolution), highlighting the importance of implementing supplier control strategies and monitoring of material properties for the desired consistency of IR performance throughout industrial scale production.[25]

4. Polymers in Modified-Release Solid Dosage Forms

Modified-release (MR) solid dosage forms are primarily enabled by *polymer-controlled* transport, where the polymer either forms a hydrating matrix (e.g., hydrophilic matrices) or a rate-limiting membrane (e.g., functional coatings). In industrial practice, MR design aims to deliver reproducible exposure (reduced peak–trough fluctuations) while maintaining manufacturability and regulatory “control strategy” readiness (critical material attributes + critical process parameters).[26]

4.1 Hydrophilic matrix systems (diffusion–swelling–erosion balance)

Hydrophilic matrices (classically hypromellose/HPMC-based) control release by a series of events which include water uptake, polymer relaxation/gel formation, and diffusion of the drug through the gel layer, where swelling and erosion process act as the co-determinant of the overall kinetics of the release. Early screening study shows that type of polymer and behavior of molecular weight can change the balance between swelling and erosion and thus shape the final release profile - that is the reason why mechanism-driven screening is increasingly considered as a QbD activity and becomes the "trial-and-error".[27] One of the most important industrial observations here is that by definition, "HPMC" is not a single material: functionality-related properties (viscosity, substitution patterns, particle size distribution and associated variability in specifications) have a role to play in gel strength problems, water penetration, and the ability to resist erosion on the part of the matrix- which can be converted into significant differences in dissolution and robustness.[28]

4.2 Scale-up scale reproducibility process sensitivity

Even for the same polymer and grade it is possible to change the hydration pathway and diffusion pathway by manufacturing route and microstructure (granule PSD, porosity, hardness, desmodensification history). In roller-compacted hypromellose matrix tablets statistically significant release changes have been associated with process parameters (e.g. roll speed), granule PSD-related attributes, highlighting the often "scale-up" is a microstructure control problem as much as a formulation problem.[29] MR reproducibility is also dissolution method and hydrodynamics sensitive. For instance, work done correlating gel strength to robustness indicated that stronger gel layers (usually attributed to increased viscosity HPMC systems) can lessen sensitivity to agitation/mechanical stress, whereas weaker gels are more susceptible to the effects of stress-driven erosion and "method dependence.[30]

4.3 Functional coatings and pH-triggered polymers

For coated MR systems, the quality of their polymers, their film formation, the plasticization and the curing/storage effects may be decisive factors. Aqueous coating systems are appealing from the industry perspective because incomplete film building or poor curing can lead to unstable or fluctuating release profiles - hence coating process development and coating post-curing thermal history are part of the release control mechanism.[31] For enteric/delayed and site specific, methacrylate copolymers (ex. Eudragit families), allow for pH dependent dissolution and permeability configuration but add complexity in elaboration of polymers, thickness otherwise and verify of performance in variable GI conditions.[32]

4.4 Bio relevance and excipient/medium interactions

Polymer performance may change as a function of ionic strength and surfactant environments An illustrative example is the observed "unexpected" behavior of HPMC matrices in dissolution media containing SDS near/below CMC attributed to polymer--surfactant interactions modifying the swelling and local solubilization conditions--that highlights the need and importance of using more often MR development, where test designs that are more biorelevant and that are based on a mechanistic understanding of the solubility processes are used.[33]



Figure 2: Relationship of polymer properties (solubility, permeability, molecular structure) and drug release mechanisms in modified-release solid dosage forms.

5. Manufacturing and Quality Control Aspects

In industrial manufacturing, the use of polymers is closely linked to processability (flow, electrostatic behavior, hygroscopicity), granulation behavior, compressibility/compactability and coating process performance. Polymer variability that appears "within specification" can still mean significant changes in manufacturability (e.g. torque/energy demand in wet granulation, ribbon density in roller compaction, tablet tensile strength or dispersion viscosity during coating), and this holds true for the more sensitive and useful paradigm of "control over polymer variables" (as opposed to "trials over formulations" only) whose management is to be based not on formulation trials but with a structured control strategy. In today's industrial best practice this is consistent with the application of science and risk-based principles to determine critical material attributes (CMAs) and critical process parameters (CPPs) that ensure protection of a desired quality profile and minimize fluctuating drift of batches (within the process).[34]

From a Quality by design point of view, polymer-linked CMAs typically comprise molecular weight/viscosity grade, degree of substitution (for cellulose derivatives), particle size distribution, moisture content and thermal properties (e.g., glass transition behaviour). These CMAs influence microstructure formation (porosity and percolation networks), which in turn has an effect on the mechanical integrity and release performance. Due to the formulation and process dependency of polymer effects, manufacturers usually try to apply fit-for-purpose analytical procedures and lifecycle control of methods to detect polymer variability early and maintain consistent control of these effects throughout commercial supply.[35] A great industrial concern is release reproducibility over time and across locations (especially in cases where suppliers, grades or processing lines change). Lifecycle management framework focuses on open definition of what is "established" in dossier and how post-approval changes are communicated and controlled- this is of high relevance in cases of changes of polymers (supplier/grade/process) where presence of dissolution/stability outcome may circulate.[36] Quality control and real-time monitoring is of a particular importance for coatings and matrix systems based on polymers, where small drifts in coating thickness/uniformity or polymer film formation may cause clinically relevant changes in performance. Process Analytical Technology (PAT) approaches, such as those involving spectroscopic and imaging tools, are widely discussed for process controls intended to monitor the coating processes and to allow consistent control of the critical attributes during the manufacturing process.[37]

Finally, polymer QA/QC must also consider for impurity and safety-related controls that may be impure polymer (e.g. of polymer manufacture or processing in the case of residual solvents, catalysts/elemental impurities). Even when polymers are excipients, however, manufacturers are expected to take controls, on a risk-based basis, consistent with frameworks of international standards for controlling impurities.[38,39]

Table 2: Important polymer properties that affect manufacturing performance and Quality Control in solid dosage forms.

Polymer attribute (CMA)	Manufacturing impact (short)	Typical QC / characterization (examples)
Particle size & morphology	Flow, segregation, granulation kinetics	Laser diffraction, microscopy/image analysis
Moisture / hygroscopicity	Sticking, compression variability, stability risk	Karl Fischer / LOD, DVS (when needed)
Viscosity / MW (grade)	Matrix gel strength, coating viscosity	Viscosity/rheology, GPC/SEC (risk-based)
Substitution degree / chemistry	Solubility, permeability, film formation	FTIR/NIR, compendial/polymer-specific assays
Thermal behavior (Tg/softening)	Compaction recovery, film coalescence	DSC/DMA (as appropriate)
Residual solvents	Safety + variability signal	GC (per solvent strategy)
Elemental impurities (catalyst residues)	Patient safety, compliance risk	ICP-MS/ICP-OES (risk-based)

6. Regulatory Considerations

Regulatory expectations for pharmaceutical polymers have to do with demonstrating that excipients are fit for intended use, consistently manufactured and appropriately controlled through the lifecycle of products. For solid dosage forms, the regulatory evaluation questions typically relate to polymers and include: (i) excipient qualification and oversight by the supplier, (ii) compendial status and setting the specifications, (iii) control of impurities, and (iv) control of change/lifecycle management. Practical guidance on excipients focuses on the organized information and evaluation of suppliers, and the correlation between excipient characteristics and desired attributes of that excipient as they relate to dosage form functionality.[40]

In many regulatory environments marketing authorization holders are expected to assure that appropriate GMP for excipients are applied based on a formalized risk assessment based on excipient source, intended use, complexity of supply chain, and prior quality defects. This is particularly true for polymers in which origin (natural vs synthetic), processing steps, and risks of variability can vary greatly.[41] For established polymers with good pharmacopeial coverage the risk of regulation may be reduced (due to the clearer expectation of identity and quality); nonetheless sponsors still have to justify the choice of grade and control the variability in the polymer product. Compendial harmonization status on major pharmacopeias can also impact on global filing.[42]

7. Effect on Patient Use and Product Performance

Polymer selection for solid dosage form design has an impact on product reliability (mechanical strength, disintegration behavior and reproducibility of release) but also the user experience for patients (swallowability, handling and dosing assurance). In practice, patient-centric design is not limited in scope to the API performance, but encompasses dosage form 'use attributes' that can make the difference between patients being able to take the medicine as intended, particularly in older patients and populations that have limited swallowing or handling abilities.[43]

From the patient perspective, polymers add to the contribution through film-coating performance, surface feel and wettability, which impact on perceived swallowability, along with likelihood of hesitation, missed doses or unsafe administration behaviours (i.e. splitter / crusher - for those not suitable). A patient-focused investigation of the characteristics of solid oral dosage forms in older people highlights how the perception of swallowability and the experience of difficulty in handling can have a significant impact on acceptability and actual use in the field.[44] In parallel, attention by regulators and sponsors to swallowability has grown and yet practices of assessment are actually heterogeneous; a review of swallowability studies conducted as part of regulatory submissions demonstrates the need for clearer approaches to best practices and more consistent designs for these studies.[45] From the product performance point of view, polymers are "structure-formers" that can stabilize the microenvironment surrounding the API, control the penetration of liquids and formation of gels, reduce variation in release-but only if the polymer attributes and polymer processing are tightly controlled. Small changes to already identical polymer grade or processing history can cause variation in terms of porosity, quality of coating or gel strength resulting in clinically significant fluctuations of onset or consistency of exposure. Therefore, the clinical value of polymer enabled technology depends on whether dosage form will be robust over the manufacturing scale, storage and real-world administration conditions, whilst also meeting the requirements of patient acceptability.

8. Future Trends

Future efforts in the pharmaceutical polymers in solid dosage forms are likely to focus on predictive design, scalable manufacturing, digital quality, and sustainability.

8.1 Predictive models for polymer enabled performance (release + stability)

Using machine learning, current trend is to predict drug release from polymeric drug delivery platforms, in the hope of minimizing trial-and-error formulation and optimize the early selection of polymer systems and process settings.[46] Alongside ML, molecular simulation and statistical learning approaches have been reviewed for predicting drug-polymer miscibility and stability risks in amorphous and polymer-rich systems for more rational carrier selection.[47] For solid dispersions and polymers-based enabling technologies, in-depth review also relates carrier choice and stabilization mechanism with production strategy (i.e. continuous processing route) reinforcing trend towards integrated "materials + process" design.[48]

8.2 Continuous manufacturing + digital quality (Pharma 4.0)

Industrial translation is forecast to make more use of continuous manufacturing platforms and better control strategies. A difference good practice guide for continuous manufacture of oral solid dosage forms related how industry is formalizing expectations for integrated unit operations, automation and end-to-end control approaches.[49] At the same time, systematized evidence syntheses regarding digital innovations for pharmaceutical manufacturing quality (PAT/RTRT, AI, modeling, IoT, data management) point to the fact that there are chances and practical hurdles of validation, data integrity, and skill gaps.[50] Framework-level work on enterprise-wide Pharma 4.0 adoption additionally hampers the demand for structured implementation models on the regulated setting.[51] Broader analyses on Industry 4.0 include the further link between digitalization and sustainability and performance results throughout pharmaceutical operations.[52]

8.3 Sustainable and bio-based polymer pipelines

Sustainability driven polymer innovation is likely to increase - notably bio-based polymers and renewable polymers - while still requiring strict control of variability, impurities and supply constancy. Reviews of bio-based polymers highlight a growth in material choice and the need for matching of properties to the limitation of the application.[53] For actors in this field, "focused pharma relevant discussion of plant-based biopolymers concerning both multifunctionality and the industrial obstacle of source dependencies (extraction, purity, molecular structure).[54]" In addition, pharmaceutics-oriented syntheses on natural polymeric materials bear witness to the range of candidates and application functions, being a constant addition to the overall process of implementing sustainability objectives, except that a link to the sustainability of process worked alone or at least in combination with constant manufacturability and readiness in terms of regulations can be ensured.[55]

9. REFERENCES

1. Zaid AN. A comprehensive review on pharmaceutical film coating: Past, present, and future. Drug Design, Development and Therapy, 2020; 14: 4613–4623.
2. Vlad RA, Pintea A, Pintea C, Rédai EM, Antonoaea P, Bîrsan M, et al. Hydroxypropyl methylcellulose—A key excipient in pharmaceutical drug delivery systems. Pharmaceutics, 2025; 17(6): 784.
3. Nikam AB, Usmani GA, Tandel N. Eudragit-based polymers: Versatile materials for controlled drug delivery systems. Polymers, 2023; 15(11): 2488.
4. Bhadoriya SS, Waeber N, Mahdi S, Gorajana S, Kuentz M. Impact of excipient variability on crystallization propensity in amorphous solid dispersions: Case studies of HPMCAS and polymeric stabilizer. European Journal of Pharmaceutical Sciences, 2026; 216: 107294.
5. Kozarewicz P, Loftsson T. Novel excipients—Regulatory challenges and perspectives—The EU insight. International Journal of Pharmaceutics, 2018; 546(1–2): 176–179.
6. Yu YB, Taraban MB, Briggs KT, Brinson RG, Marino JP. Excipient innovation through precompetitive research. Pharmaceutical Research, 2021; 38(12): 2179–2184.
7. Food and Drug Administration. Center for Drug Evaluation and Research, Office of New Drugs; Novel excipient review pilot program. Federal Register, 2021; 86(171): 50365–50366.
8. Arshad MS, Zafar S, Yousef B, Alyassin Y, Ali R, Alasiri A, et al. Emerging technologies enabling improved solid oral dosage form manufacturing and processing. Advanced Drug Delivery Reviews, 2021; 178: 113840.
9. Kovačević M, Zvonar Pobirk A, German Ilić I. The effect of polymeric binder type and concentration on flow and dissolution properties of SMEDDS loaded mesoporous silica-based granules. European Journal of Pharmaceutical Sciences, 2024; 193: 106582.
10. Berardi A, Janssen PHM, Dickhoff BHJ. Technical insight into potential functional-related characteristics (FRCs) of sodium starch glycolate, croscarmellose sodium and crospovidone. Journal of Drug Delivery Science and Technology, 2022; 70: 103261.
11. Denduyver P, Vervaet C, Vanhoorne V. Studying the API distribution of controlled release formulations produced via continuous twin-screw wet granulation: Influence of matrix former, filler and process parameters. Pharmaceutics, 2024; 16(3): 341.
12. Salawi A. Pharmaceutical coating and its different approaches: A review. Polymers, 2022; 14(16): 3318.
13. Janssen PHM, Dickhoff BHJ, Ferreira A, Gamble J, Shinebaum R, Tobyn M. Understanding the impact of excipient variability on oral solid dosage form performance: A possible role for multivariate data analysis, in the form of principal component

analysis. Journal of Pharmaceutical Sciences, 2025; 114(12): 104021.
14. Muehlenfeld C, Duffy P, Yang F, Zermeño Pérez D, El-Saleh F, Durig T. Selection of pharmaceutical excipients for additive manufacturing: A comprehensive review on properties and applications. Pharmaceutics, 2024.
15. Nair AR, Lakshman YD, Anand VSK, Sree KSN, Bhat K, Dengale SJ. Overview of extensively employed polymeric carriers in solid dispersion technology. AAPS PharmSciTech, 2020; 21(8): 309.
16. Benalaya I, Alves G, Lopes J, Silva LR. A review of natural polysaccharides: Sources, characteristics, properties, food, and pharmaceutical applications. International Journal of Molecular Sciences, 2024; 25(2): 1322.
17. Garg T, Arora S, Pahwa R. Cellulose and its derivatives: Structure, modification, and application in controlled drug delivery. Future Journal of Pharmaceutical Sciences, 2025; 11: 76.
18. Kurakula M, Rao GSNK. Pharmaceutical assessment of polyvinylpyrrolidone (PVP): As excipient from conventional to controlled delivery systems with a spotlight on COVID-19 inhibition. Journal of Drug Delivery Science and Technology, 2020; 60: 102046.
19. Christoforou I, Kalatzis A, Siamidi A, Vlachou M, Pispas S, Pippa N, et al. The ubiquitous use of polyethylene glycol in pharmaceutical design and development: Technological aspects and future perspectives. Nanomaterials, 2025; 15(23): 1762.
20. Kulinowski P, Młynarczyk A, Sznitowska M. Effect of excipient variability on drug product performance. European Journal of Pharmaceutics and Biopharmaceutics, 2011; 78(2): 283–289.
21. Desai PM, Liew CV, Heng PWS. Review of disintegrants and the disintegration phenomena. Journal of Pharmaceutical Sciences, 2016; 105(9): 2545–2555.
22. Steffens KE, Wagner KG. Immediate-release formulations produced via twin-screw melt granulation: Systematic evaluation of the addition of disintegrants. AAPS PharmSciTech, 2021; 22(5): 183.
23. Köster C, Kleinebudde P. Evaluation of binders in twin-screw wet granulation – Optimization of tabletability. International Journal of Pharmaceutics, 2024; 659: 124290.
24. Patel DB, Patel NM, Prajapati SB. Influence of binder type and concentration on granule and tablet properties: A systematic study. International Journal of Pharmaceutics, 2020; 587: 119650.
25. Kim JY, Choi DH. Control strategy for excipient variability in the Quality by Design approach using statistical analysis and predictive model: Effect of microcrystalline cellulose variability on design space. Pharmaceutics, 2022; 14(11): 2416.
26. Atre P, Rizvi SAA. Advances in oral solid drug delivery systems: Quality by design approach in development of controlled release tablets. BioChem, 2025; 5(2): 9.
27. Sousa AS, Serra J, Estevens C, Costa R, Ribeiro AJ. Unveiling swelling and erosion dynamics: Early development screening of mirabegron extended release tablets. AAPS PharmSciTech, 2024; 25: 277.
28. Goldoozian S, Mohylyuk V, Dashevskiy A, Bodmeier R. Gel strength of hydrophilic matrix tablets in terms of in vitro robustness. Pharmaceutical Research, 2021; 38(7): 1297–1306.
29. Dular Vovko A, Hodžić B, Brec T, Hudovornik G, Vrečer F. Influence of formulation factors, process parameters, and selected quality attributes on carvedilol release from roller-compacted hypromellose-based matrix tablets. Pharmaceutics, 2022; 14(4): 712.
30. Ojsteršek T, Hudovornik G, Vrečer F. Influence of selected hypromellose functionality-related characteristics and soluble/insoluble filler ratio on carvedilol release from matrix tablets. Pharmaceutics, 2025.
31. Nikam A, Sahoo PR, Musale S, Pagar RR, Paiva-Santos AC, Giram PS, et al. A systematic overview of Eudragit® based copolymer for smart healthcare. Polymers, 2023.
32. Ahmed TA. Aqueous polymeric coatings: New opportunities in drug delivery systems. In: Advanced Drug Delivery Systems in the Treatment of Diabetes. Elsevier, 2020.
33. Rede K, Felicijan T, Bogataj M. Exploring the unexpected behavior of HPMC matrix tablets in dissolution media with SDS. Journal of Drug Delivery Science and Technology, 2021; 66: 102801.
34. International Council for Harmonisation. ICH Q13: Continuous manufacturing of drug substances and drug products (Step 4 Guideline, 16 November 2022). 2022.
35. International Council for Harmonisation. ICH Q14: Analytical procedure development (Guideline, 16 November 2023). 2023.
36. International Council for Harmonisation. ICH Q12: Technical and regulatory considerations for pharmaceutical product lifecycle management (Step 4 Guideline, 19 November 2019). 2019.
37. Korasa K, Vrečer F. Overview of PAT process analysers applicable in monitoring of film coating unit operations for manufacturing of solid oral dosage forms. European Journal of Pharmaceutical Sciences, 2018; 111: 278–292.
38. International Council for Harmonisation. ICH Q3C(R8): Impurities: Guideline for residual solvents (Step 4 Guideline, 22 April 2021). 2021.
39. International Council for Harmonisation. ICH Q3D(R2): Guideline for elemental impurities (Final version, adopted 26 April 2022), 2022.
40. International Pharmaceutical Excipients Council (IPEC) Federation. Qualification of excipients for use in pharmaceuticals. 2nd ed. 2020.
41. Pharmaceutical Inspection Co-operation Scheme (PIC/S). PI 045-1: Guidelines on the formalised risk

assessment for ascertaining the appropriate GMP for excipients of medicinal products for human use (Entry into force: 1 July 2018). 2018.
42. European Directorate for the Quality of Medicines & HealthCare (EDQM). Harmonisation status for excipient monographs (PDG), 2025.
43. Shariff Z, Kirby D, Missaghi S, Rajabi-Siahboomi A, Maidment I. Patient-centric medicine design: Key characteristics of oral solid dosage forms that improve adherence and acceptance in older people. Pharmaceutics, 2020; 12(10): 905.
44. Hummler H, Page S, Weitschies W, Seidlitz A. Influence of solid oral dosage form characteristics on swallowability, visual perception, and handling in older adults. Pharmaceutics, 2023; 15(4): 1315.
45. McGuire MR, Chen AM, Li X, Wen H. Designs of clinical swallowability assessments of solid oral dosage forms in regulatory submissions. International Journal of Pharmaceutics, 2024.
46. Aghajanpour S, Amiriara H, Esfandyari-Manesh M, Ebrahimnejad P, Jeelani H, Henschel A, et al. Utilizing machine learning for predicting drug release from polymeric drug delivery systems. Computers in Biology and Medicine, 2025.
47. Walden DM, Bundey Y, Jagarapu A, Antontsev V, Chakravarty K, Varshney J. Molecular simulation and statistical learning methods toward predicting drug–polymer amorphous solid dispersion miscibility, stability, and formulation design. Molecules, 2021; 26(1): 182.
48. Han J, Tang M, Yang Y, Sun W, Yue Z, Zhang Y, Zhu Y, Liu X, Wang J. Amorphous solid dispersions: Stability mechanism, design strategy and key production technique of hot melt extrusion. International Journal of Pharmaceutics, 2023; 123490.
49. International Society for Pharmaceutical Engineering. Good Practice Guide: Continuous Manufacturing of Oral Solid Dosage Forms, 2022.
50. Fitzgerald L, Niarchou E, Jones I, Naughton B. Emerging digital innovations in pharmaceutical manufacturing quality: A systematised review. Journal of Pharmaceutical Innovation, 2026; 21: 46.
51. Phiri VJ, Battas I, Semmar A, Medromi H, Moutaouakkil F. Towards enterprise-wide Pharma 4.0 adoption. Sustainable Operations and Computers, 2025.
52. Sharma D, Patel P, Shah M. A comprehensive study on Industry 4.0 in the pharmaceutical industry for sustainable development. Sustainable Operations and Computers, 2023.
53. Righetti GIC, Faedi F, Famulari A. Embracing sustainability: The world of bio-based polymers in a mini review. Polymers, 2024; 16(7): 950.
54. Tharaka DN, Tissera ND, Dahanayake D, Dimuthumali D, Priyadarshana G. Plant-based biopolymers in the pharmaceutical sector. In: Chakraborty R, Roy S, editors. Biopolymers from Plant Origin for Environmental Sustainability. Springer, 2026; p. 121–143.
55. Jain S, Jain A, Jain R, Chouhan NS. Potential of natural polymeric materials in pharmaceutics. Journal of Functional Biomaterials, 2024; 2: 100014.